George J. Eiermann

(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes

George R. Lankas, Barbara Leiting, Ranabir Sinha Roy et al. · Diabetes · 2005 · 491 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Alessandro Pocai, Paul E. Carrington, Jennifer R. Adams et al. · Diabetes · 2009 · 407 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy

Robert W. Myers, Hong-Ping Guan, Juliann Ehrhart et al. · Science · 2017 · 344 citations

Life Sciences, Biochemistry, Pharmacology +17

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-<i>t</i>-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor

John W. Gillard, A W Ford‐Hutchinson, Chi-Chung Chan et al. · Canadian Journal of Physiology and Pharmacology · 1989 · 328 citations

Medicine, Biochemistry, Pharmacology +14